8api - Revision history

OCA at 12:23, 10 January 2024

2024-01-10T12:23:37Z

← Older revision		Revision as of 12:23, 10 January 2024
Line 1:		Line 1:

	==THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM==		==THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM==
	<StructureSection load='8api' size='340' side='right' caption='[[8api]], [[Resolution\|resolution]] 3.10Å' scene=''>		<StructureSection load='8api' size='340' side='right'caption='[[8api]], [[Resolution\|resolution]] 3.10Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[8api]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=8API FirstGlance]. <br>		<table><tr><td colspan='2'>[[8api]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8API FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>~~</td></tr>~~		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 3.1Å</td></tr>
	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[7api\|7api]], [[9api\|9api]]~~</td></tr>		<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=8api FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8api OCA], [~~http~~://pdbe.org/8api PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=8api RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/8api PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=8api ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8api FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8api OCA], [https://pdbe.org/8api PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8api RCSB], [https://www.ebi.ac.uk/pdbsum/8api PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8api ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
	[~~[http~~://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD) [MIM:[~~http~~://omim.org/entry/613490 613490]]. A disorder whose most common manifestation is emphysema, which becomes evident by the third to fourth decade. A less common manifestation of the deficiency is liver disease, which occurs in children and adults, and may result in cirrhosis and liver failure. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age.<ref>PMID:1905728</ref> <ref>PMID:2390072</ref> <ref>PMID:2227940</ref>		[https://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN] Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD) [MIM:[https://omim.org/entry/613490 613490]. A disorder whose most common manifestation is emphysema, which becomes evident by the third to fourth decade. A less common manifestation of the deficiency is liver disease, which occurs in children and adults, and may result in cirrhosis and liver failure. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age.<ref>PMID:1905728</ref> <ref>PMID:2390072</ref> <ref>PMID:2227940</ref>
	== Function ==		== Function ==
	[~~[http~~://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.[:]<ref>PMID:1906855</ref> <ref>PMID:1406456</ref> Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).[:]<ref>PMID:1906855</ref> <ref>PMID:1406456</ref>		[https://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN] Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.[:]<ref>PMID:1906855</ref> <ref>PMID:1406456</ref> Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).[:]<ref>PMID:1906855</ref> <ref>PMID:1406456</ref>
	== Evolutionary Conservation ==		== Evolutionary Conservation ==
	[[Image:Consurf_key_small.gif\|200px\|right]]		[[Image:Consurf_key_small.gif\|200px\|right]]
	Check<jmol>		Check<jmol>
	<jmolCheckbox>		<jmolCheckbox>
	<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/ap/8api_consurf.spt"</scriptWhenChecked>		<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/ap/8api_consurf.spt"</scriptWhenChecked>
	<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>		<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
	<text>to colour the structure by Evolutionary Conservation</text>		<text>to colour the structure by Evolutionary Conservation</text>
Line 33:		Line 33:

	==See Also==		==See Also==
	*[[Alpha-1-antitrypsin\|Alpha-1-antitrypsin]]		*[[Alpha-1-antitrypsin 3D structures\|Alpha-1-antitrypsin 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 39:		Line 39:
	</StructureSection>		</StructureSection>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Deisenhofer, J]]		[[Category: Large Structures]]
	[[Category: Huber, R]]		[[Category: Deisenhofer J]]
	[[Category: Loebermann, H]]		[[Category: Huber R]]
	[[Category: Tokuoka, R]]		[[Category: Loebermann H]]
	~~[[Category: Proteinase inhibitor~~]]		[[Category: Tokuoka R]]

OCA at 23:30, 5 August 2016

2016-08-05T23:30:27Z

← Older revision		Revision as of 23:30, 5 August 2016
Line 1:		Line 1:

	==THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM==		==THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM==
	<StructureSection load='8api' size='340' side='right' caption='[[8api]], [[Resolution\|resolution]] 3.10Å' scene=''>		<StructureSection load='8api' size='340' side='right' caption='[[8api]], [[Resolution\|resolution]] 3.10Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[7api\|7api]], [[9api\|9api]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[7api\|7api]], [[9api\|9api]]</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=8api FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8api OCA], [http://www.rcsb.org/pdb/explore.do?structureId=8api RCSB], [http://www.ebi.ac.uk/pdbsum/8api PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=8api FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8api OCA], [http://pdbe.org/8api PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=8api RCSB], [http://www.ebi.ac.uk/pdbsum/8api PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=8api ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 19:		Line 20:
	<text>to colour the structure by Evolutionary Conservation</text>		<text>to colour the structure by Evolutionary Conservation</text>
	</jmolCheckbox>		</jmolCheckbox>
	</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary\|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/~~chain_selection~~.php?pdb_ID=~~2ata~~ ConSurf].		</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary\|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=8api ConSurf].
	<div style="clear:both"></div>		<div style="clear:both"></div>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 29:		Line 30:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
			<div class="pdbe-citations 8api" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 15:38, 21 December 2014

2014-12-21T15:38:23Z

← Older revision		Revision as of 15:38, 21 December 2014
Line 1:		Line 1:
	~~{{STRUCTURE_8api\| PDB=8api \| SCENE= }}~~		==THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM==
	===THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM===		<StructureSection load='8api' size='340' side='right' caption='[[8api]], [[Resolution\|resolution]] 3.10Å' scene=''>
	~~{{ABSTRACT_PUBMED_2785270}}~~		== Structural highlights ==
			<table><tr><td colspan='2'>[[8api]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=8API FirstGlance]. <br>
			</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
			<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[7api\|7api]], [[9api\|9api]]</td></tr>
			<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=8api FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8api OCA], [http://www.rcsb.org/pdb/explore.do?structureId=8api RCSB], [http://www.ebi.ac.uk/pdbsum/8api PDBsum]</span></td></tr>
			</table>
			== Disease ==
			[[http://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD) [MIM:[http://omim.org/entry/613490 613490]]. A disorder whose most common manifestation is emphysema, which becomes evident by the third to fourth decade. A less common manifestation of the deficiency is liver disease, which occurs in children and adults, and may result in cirrhosis and liver failure. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age.<ref>PMID:1905728</ref> <ref>PMID:2390072</ref> <ref>PMID:2227940</ref>
			== Function ==
			[[http://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.[:]<ref>PMID:1906855</ref> <ref>PMID:1406456</ref> Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).[:]<ref>PMID:1906855</ref> <ref>PMID:1406456</ref>
			== Evolutionary Conservation ==
			[[Image:Consurf_key_small.gif\|200px\|right]]
			Check<jmol>
			<jmolCheckbox>
			<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/ap/8api_consurf.spt"</scriptWhenChecked>
			<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
			<text>to colour the structure by Evolutionary Conservation</text>
			</jmolCheckbox>
			</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary\|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/chain_selection.php?pdb_ID=2ata ConSurf].
			<div style="clear:both"></div>
			<div style="background-color:#fffaf0;">
			== Publication Abstract from PubMed ==
			The S variant of the human alpha 1-antitrypsin with E-264----V, is responsible for a mild alpha 1-antitrypsin deficiency quite common in the European population. S protein specifically cleaved at the susceptible peptide bond was crystallized and its crystal structure determined and refined to 3.1 A resolution. The S variant crystallizes isomorphous to the normal M variant. The difference Fourier electron density map shows the E----V change as outstanding residual density. In addition, small structural changes of the main polypeptide chain radiate from the site of mutation and affect parts far removed from it. By the mutation, internal hydrogen bonds and salt linkages of E-264 to Y-38 and K-487, respectively, are lost. They cause the far-reaching slight distortions and are probably related to the reduced thermal stability of the S mutant. They may also be responsible for slower folding of the polypeptide chain and the clinical symptoms of alpha 1-antitrypsin deficiency. In a theoretical study by molecular dynamics methods simulations of the M and S proteins were made and the results analysed with respect to structural and dynamic properties and compared with the experimental results. There is a significant correlation between experimental and theoretical results in some respects.

	~~==Disease==~~		The S variant of human alpha 1-antitrypsin, structure and implications for function and metabolism.,Engh R, Lobermann H, Schneider M, Wiegand G, Huber R, Laurell CB Protein Eng. 1989 Mar;2(6):407-15. PMID:2785270<ref>PMID:2785270</ref>
	~~[[http://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Defects in SERPINA1 are the cause~~ of alpha-1-antitrypsin ~~deficiency (A1ATD) [MIM:[http://omim~~.~~org/entry/613490 613490]]. A disorder whose most common manifestation is emphysema~~, ~~which becomes evident by the third to fourth decade. A less common manifestation of the deficiency is liver disease~~, ~~which occurs in children and adults~~, ~~and may result in cirrhosis and liver failure. Environmental factors~~, ~~particularly cigarette smoking~~, ~~greatly increase the risk of emphysema at an earlier age~~.~~<ref>PMID~~:~~1905728</ref><ref>~~PMID:~~2390072</ref>~~<ref>PMID:~~2227940~~</ref>

	~~==Function==~~		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	~~[[http:~~/~~/www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Inhibitor of serine proteases. Its primary target is elastase~~, ~~but it also has~~ a ~~moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator~~. ~~The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin~~.[:]<ref>PMID:1906855</ref><ref>PMID:1406456</ref> Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of ~~the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE)~~.~~[:]~~<~~ref~~>~~PMID:1906855~~</~~ref><ref~~>~~PMID:1406456</ref>~~		</div>

	~~==About this Structure==~~
	[[8api]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].

	==See Also==		==See Also==
	*[[Alpha-1-antitrypsin\|Alpha-1-antitrypsin]]		*[[Alpha-1-antitrypsin\|Alpha-1-antitrypsin]]
			== References ==
	==~~Reference~~==		<references/>
	~~<ref group="xtra">PMID:002785270</ref>~~<references ~~group="xtra"~~/><~~references~~/>		__TOC__
			</StructureSection>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Deisenhofer, J.]]		[[Category: Deisenhofer, J]]
	[[Category: Huber, R.]]		[[Category: Huber, R]]
	[[Category: Loebermann, H.]]		[[Category: Loebermann, H]]
	[[Category: Tokuoka, R.]]		[[Category: Tokuoka, R]]
	[[Category: Proteinase inhibitor]]		[[Category: Proteinase inhibitor]]

OCA at 07:23, 25 March 2013

2013-03-25T07:23:15Z

← Older revision		Revision as of 07:23, 25 March 2013
Line 1:		Line 1:
	~~[[Image:8api.png\|left\|200px]]~~

	{{STRUCTURE_8api\| PDB=8api \| SCENE= }}		{{STRUCTURE_8api\| PDB=8api \| SCENE= }}
			===THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM===
			{{ABSTRACT_PUBMED_2785270}}

	===~~THE S VARIANT OF HUMAN ALPHA1~~-~~ANTITRYPSIN~~, ~~STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM===~~		==Disease==
			[[http://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD) [MIM:[http://omim.org/entry/613490 613490]]. A disorder whose most common manifestation is emphysema, which becomes evident by the third to fourth decade. A less common manifestation of the deficiency is liver disease, which occurs in children and adults, and may result in cirrhosis and liver failure. Environmental factors, particularly cigarette smoking, greatly increase the risk of emphysema at an earlier age.<ref>PMID:1905728</ref><ref>PMID:2390072</ref><ref>PMID:2227940</ref>

	~~{{ABSTRACT_PUBMED_2785270}}~~		==Function==
			[[http://www.uniprot.org/uniprot/A1AT_HUMAN A1AT_HUMAN]] Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.[:]<ref>PMID:1906855</ref><ref>PMID:1406456</ref> Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).[:]<ref>PMID:1906855</ref><ref>PMID:1406456</ref>

	==About this Structure==		==About this Structure==
Line 14:		Line 16:

	==Reference==		==Reference==
	<ref group="xtra">PMID:002785270</ref><references group="xtra"/>		<ref group="xtra">PMID:002785270</ref><references group="xtra"/><references/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Deisenhofer, J.]]		[[Category: Deisenhofer, J.]]

OCA at 22:36, 20 October 2012

2012-10-20T22:36:29Z

← Older revision		Revision as of 22:36, 20 October 2012
Line 8:		Line 8:

	==About this Structure==		==About this Structure==
	[[8api]] is a 2 chain structure ~~of [[Alpha-1-antitrypsin]]~~ with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].		[[8api]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].

	==See Also==		==See Also==

OCA: Protected "8api" [edit=sysop:move=sysop]

2012-07-27T16:53:41Z

Protected "8api" [edit=sysop:move=sysop]

← Older revision	Revision as of 16:53, 27 July 2012
(No difference)

OCA at 16:53, 27 July 2012

2012-07-27T16:53:40Z

← Older revision		Revision as of 16:53, 27 July 2012
Line 1:		Line 1:
	~~{{Seed}}~~
	[[Image:8api.png\|left\|200px]]		[[Image:8api.png\|left\|200px]]

	~~<!--~~
	~~The line below this paragraph, containing "STRUCTURE_8api", creates the "Structure Box" on the page.~~
	~~You may change the PDB parameter (which sets the PDB file loaded into the applet)~~
	~~or the SCENE parameter (which sets the initial scene displayed when the page is loaded),~~
	~~or leave the SCENE parameter empty for the default display.~~
	~~-->~~
	{{STRUCTURE_8api\| PDB=8api \| SCENE= }}		{{STRUCTURE_8api\| PDB=8api \| SCENE= }}

	===THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM===		===THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM===


	~~<!--~~
	~~The line below this paragraph, {{ABSTRACT_PUBMED_2785270}}, adds the Publication Abstract to the page~~
	~~(as it appears on PubMed at http://www.pubmed.gov), where 2785270 is the PubMed ID number.~~
	~~-->~~
	{{ABSTRACT_PUBMED_2785270}}		{{ABSTRACT_PUBMED_2785270}}

	==About this Structure==		==About this Structure==
	~~8API~~ is a 2 ~~chains~~ structure of ~~sequences~~ from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].		[[8api]] is a 2 chain structure of [[Alpha-1-antitrypsin]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].

			==See Also==
			*[[Alpha-1-antitrypsin\|Alpha-1-antitrypsin]]

	==Reference==		==Reference==
	<ref group="xtra">PMID:~~2785270~~</ref><references group="xtra"/>		<ref group="xtra">PMID:002785270</ref><references group="xtra"/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Deisenhofer, J.]]		[[Category: Deisenhofer, J.]]
Line 30:		Line 21:
	[[Category: Tokuoka, R.]]		[[Category: Tokuoka, R.]]
	[[Category: Proteinase inhibitor]]		[[Category: Proteinase inhibitor]]

	~~''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Feb 18 10:12:54 2009''~~

OCA at 08:12, 18 February 2009

2009-02-18T08:12:55Z

← Older revision		Revision as of 08:12, 18 February 2009
Line 20:		Line 20:

	==About this Structure==		==About this Structure==
	8API is a ~~[[Single protein]]~~ structure of ~~sequence~~ from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].		8API is a 2 chains structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].

	==Reference==		==Reference==
	The S variant of human alpha 1-antitrypsin, structure and implications for function and metabolism., Engh R, Lobermann H, Schneider M, Wiegand G, Huber R, Laurell CB, Protein Eng. 1989 Mar;2(6):407-15. PMID:~~[http:~~//~~www.ncbi.nlm.nih.gov/pubmed/2785270 2785270]~~		<ref group="xtra">PMID:2785270</ref><references group="xtra"/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	~~[[Category: Single protein]]~~
	[[Category: Deisenhofer, J.]]		[[Category: Deisenhofer, J.]]
	[[Category: Huber, R.]]		[[Category: Huber, R.]]
Line 32:		Line 31:
	[[Category: Proteinase inhibitor]]		[[Category: Proteinase inhibitor]]

	''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on ~~Fri Jul 11~~ 12:~~59:42 2008~~''		''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Feb 18 10:12:54 2009''

OCA at 09:59, 11 July 2008

2008-07-11T09:59:42Z

← Older revision		Revision as of 09:59, 11 July 2008
Line 1:		Line 1:
	[[Image:8api.~~gif~~\|left\|200px]]		{{Seed}}
			[[Image:8api.png\|left\|200px]]

	<!--		<!--
Line 9:		Line 10:
	{{STRUCTURE_8api\| PDB=8api \| SCENE= }}		{{STRUCTURE_8api\| PDB=8api \| SCENE= }}

	~~'''~~THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM~~'''~~		===THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM===


	~~==Overview==~~		<!--
	The ~~S variant of the human alpha 1-antitrypsin with E-264----V~~, ~~is responsible for a mild alpha 1-antitrypsin deficiency quite common in the European population. S protein specifically cleaved at~~ the ~~susceptible peptide bond was crystallized and its crystal structure determined and refined to 3.1 A resolution. The S variant crystallizes isomorphous~~ to the ~~normal M variant~~. ~~The difference Fourier electron density map shows the E----V change as outstanding residual density~~. ~~In addition~~, ~~small structural changes of the main polypeptide chain radiate from~~ the ~~site of mutation and affect parts far removed from it~~. ~~By the mutation, internal hydrogen bonds and salt linkages of E~~-~~264 to Y~~-38 and K-487, respectively, are lost. They cause the far-reaching slight distortions and are probably related to the reduced thermal stability of the S mutant. They may also be responsible for slower folding of the polypeptide chain and the clinical symptoms of alpha 1-antitrypsin deficiency. In a theoretical study by molecular dynamics methods simulations of the M and S proteins were made and the results analysed with respect to structural and dynamic properties and compared with the experimental results. There is a significant correlation between experimental and theoretical results in some respects.		The line below this paragraph, {{ABSTRACT_PUBMED_2785270}}, adds the Publication Abstract to the page
			(as it appears on PubMed at http://www.pubmed.gov), where 2785270 is the PubMed ID number.
			-->
			{{ABSTRACT_PUBMED_2785270}}

	==About this Structure==		==About this Structure==
Line 27:		Line 31:
	[[Category: Tokuoka, R.]]		[[Category: Tokuoka, R.]]
	[[Category: Proteinase inhibitor]]		[[Category: Proteinase inhibitor]]
	''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on ~~Sun May 4 22~~:48:37 2008''
			''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Jul 11 12:59:42 2008''

OCA at 19:48, 4 May 2008

2008-05-04T19:48:38Z

← Older revision		Revision as of 19:48, 4 May 2008
Line 1:		Line 1:
	[[Image:8api.gif\|left\|200px]]		[[Image:8api.gif\|left\|200px]]

	{{Structure		<!--
	\|PDB~~= 8api \|SIZE=350\|CAPTION= <scene name='initialview01'>8api</~~scene>, ~~resolution 3~~.~~1Å~~		The line below this paragraph, containing "STRUCTURE_8api", creates the "Structure Box" on the page.
	~~\|SITE=~~		You may change the PDB parameter (which sets the PDB file loaded into the applet)
	~~\|LIGAND= <scene name='pdbligand=CYS:CYSTEINE'>CYS</scene>, <scene name='pdbligand=MAN:ALPHA~~-D-~~MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene~~>		or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
	\|~~ACTIVITY~~=		or leave the SCENE parameter empty for the default display.
	\|~~GENE~~=		-->
	~~\|DOMAIN=~~		{{STRUCTURE_8api\| PDB=8api \| SCENE= }}
	~~\|RELATEDENTRY=~~
	\|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=8api FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8api OCA], [http://www.ebi.ac.uk/pdbsum/8api PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=8api RCSB]</span>
	}}

	'''THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM'''		'''THE S VARIANT OF HUMAN ALPHA1-ANTITRYPSIN, STRUCTURE AND IMPLICATIONS FOR FUNCTION AND METABOLISM'''
Line 19:		Line 16:

	==About this Structure==		==About this Structure==
	8API is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry ~~6API~~. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].		8API is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=6api 6api]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8API OCA].

	==Reference==		==Reference==
Line 29:		Line 26:
	[[Category: Loebermann, H.]]		[[Category: Loebermann, H.]]
	[[Category: Tokuoka, R.]]		[[Category: Tokuoka, R.]]
	[[Category: ~~proteinase~~ inhibitor]]		[[Category: Proteinase inhibitor]]
			''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 22:48:37 2008''
	''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on ~~Mon Mar 31 05~~:44:59 2008''